Key facts
- Therini Bio’s last known valuation is $100.0M (May 2025).
- It has raised $101.5M across 2 recorded rounds; the latest was Later Stage VC ($74.9M) in Mar 2023.
- Notable investors include National Institutes of Health, University of California, Dolby Family Ventures, SV Health Investors, Angelini Ventures — 15 tracked in total.
- Therini Bio has filed 3 Form Ds with the SEC since 2020, most recently Sep 2025 ($74.9M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Therini Bio
Funding rounds
2 roundsAbout Therini Bio
Developer of biotechnology drugs designed to offer a potential treatment to protect the nervous system from multiple sclerosis damage. The company is engaged in the development of antibodies that are dedicated to the treatment of neuroinflammatory diseases due to vascular dysfunction, enabling healthcare providers to treat their patients and improve their lives.
- Sector
- Healthcare
- HQ
- Sacramento, CA, United States
- Founded
- 2016
- Employees
- 9
- Website
- therinibio.com/
- Ownership
- Privately Held (backing)
Therini Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Therini Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Therini Bio in its N-PORT filings yet. We sweep new filings monthly.